Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Conditions

• Intraductal Papillary Mucinous Neoplasm of the Pancreas
• Recurrent Pancreatic Cancer
• Stage IA Pancreatic Cancer
• Stage IB Pancreatic Cancer
• Stage IIA Pancreatic Cancer
• Stage IIB Pancreatic Cancer
• Stage III Pancreatic Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• erlotinib hydrochloride — DRUG
  Given PO
• conventional surgery — PROCEDURE
  Undergo pancreatectomy
• immunohistochemistry staining method — OTHER
  Correlative studies
• protein expression analysis — GENETIC
  Correlative studies
• biopsy — PROCEDURE
  Correlative studies
• pharmacological study — OTHER
  Correlative studies
• laboratory biomarker analysis — OTHER
  Correlative studies

Study Details

Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. This phase II trial is studying how well erlotinib hydrochloride works in treating patients with pancreatic cancer that can be removed by surgery

Key Dates

First listed

Jun 5, 2007

Start date

Jun 30, 2007

Status verified

Mar 2014

Primary completion

Feb 28, 2010

Completion

Sep 30, 2013

Study Design

Enrollment

6 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (enzyme inhibitor therapy)
  Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.

Primary Outcome Measure

Reduction in Number of Positive IPMN Celss and Staining Intensity After Treatment [ Time Frame: Pre-treatment and post-treatment ]

Locations (1)

Find similar trials in Orange, CA